(ventricular asymmetry) that were thought to be unrelated to ZIKV infection.
Our findings suggest that prenatal ultrasonography in ZIKV-infected pregnant women can detect ZIKV-associated morphologic changes in the fetus and thus may inform decision making among such women who may be considering pregnancy termination. 
Clonal Hematopoiesis and Atherosclerosis
To the Editor: Jaiswal and colleagues (July 13 issue) 1 report that the presence of clonal hematopoiesis of indeterminate potential (CHIP) was associated with coronary heart disease. However, the use of the JAK2 V617F mutation as a marker of CHIP may be misleading, particularly when the mutant allele burden is high (up to 52% in this study). Unlike all the other mutations that were evaluated by the authors, JAK2 V617F is an initiating mutation that causes deregulated production of red cells and platelets. 2 It is a major criterion in the classification of the World Health Organization (WHO) for a diagnosis of myeloproliferative neoplasms, diseases that are often diagnosed after major thrombosis, including myocardial infarctions.
3-5 Jaiswal and colleagues considered that leukocyte counts can be used to rule out myeloproliferative neoplasms, whereas hematocrit and platelet counts are much more relevant for this purpose, especially in polycythemia vera and essential thrombocythemia. In the absence of full blood counts, one could speculate that many of the patients with a high JAK2 V617F allele burden are more likely to have undiagnosed myeloproliferative neoplasms than to be healthy CHIP carriers. Therefore, we suggest that the JAK2 V617F mutation should not be included in the definition of CHIP because of its specific involvement in the pathogenesis of myeloproliferative neoplasms. To the Editor: Jaiswal et al. report the results of four case-control studies that confirm a near doubling in the risk of coronary heart disease in patients with CHIP, 1 a finding that was first reported in the Journal in 2014. 2 The authors postulate that two mechanisms may be involved: the promotion of inflammatory responses, as supported in a study involving Tet2 knockout mice, and an increase in the number of myeloid cells, a finding that appears to be more relevant for patients with JAK2 mutations, which confer a much larger risk than the more common DNMT3A, TET2, and ASXL1 mutations, in which blood counts remain normal.
However, the authors do not provide data relating to red-cell distribution width, which is the only blood-cell index that has been shown to have a significant association with CHIP 2 and which has been associated with an unexplained increase in all-cause mortality in an aging population. 3, 4 In understanding how CHIP promotes atherosclerosis, it is important to explore the causal relationship between clonal hematopoiesis and red-cell anisocytosis to determine whether these are independent or associated risk factors for cardiovascular disease. The authors reply: Cassinat et al. correctly state that patients with myeloproliferative neoplasms have an elevated risk of thrombosis, which several studies have concluded is related to the degree of leukocytosis but not thrombocytosis or erythrocytosis. [1] [2] [3] In our previous study, five of the six patients with JAK2-mutated CHIP did not have any abnormalities in the complete blood count and thus would not have met the WHO criteria for either polycythemia vera or essential thrombocythemia. 4 In the current study, data regarding the complete blood count were available for patients from the Malmö Diet and Cancer prospective cohort study. Of the two patients with JAK2 mutations in that cohort, one had no blood-count abnormalities and the other had mild thrombocytosis (463,000 platelets per microliter). It is possible that clinically evident myeloproliferative neoplasms will be diagnosed in some, or even most, of these patients after several years. However, we believe it is premature to conclude that JAK2 V617F should not be included in the definition of CHIP on the basis of current information.
Phillips et al. suggest that increased red-cell anisocytosis may be associated with both CHIP and atherosclerotic cardiovascular disease, thereby pointing to the causal biologic features that link these phenomena. Data on red-cell distribution width-standard deviation (RDW-SD) were available from the complete blood count in patients in the Malmö Diet and Cancer cohort. In this relatively small sample, CHIP was not significantly associated with the RDW-SD. The presence of CHIP was associated with an increase in the RDW-SD of 1.85 fl (P = 0.32), after adjustment for age, sex, coronary heart disease status, type 2 diabetes status, and smoking history. The inclu-sion of the RDW-SD in a Cox proportional-hazards model for the development of coronary heart disease did not affect the risk estimate associated with CHIP (hazard ratio, 1.99; 95% confidence interval, 1.26 to 3.13), after adjustment for RDW-SD, age, sex, hypertension, type 2 diabetes status, smoking history, and levels of high-density lipoprotein cholesterol and total cholesterol. On the basis of this limited sample, we found no evidence that red-cell anisocytosis, as indicated by an elevated RDW-SD, mediates the association between CHIP and atherosclerotic cardiovascular disease. Siddhartha Jaiswal, M.D., Ph.D.
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To the Editor: Le et al. compared the efficacy of amphotericin B, administered intravenously, with that of itraconazole, administered orally, in the treatment of talaromycosis and found that amphotericin B was superior. The survival benefit was thought to be associated with greater fungicidal activity of amphotericin B, but the authors did not take into account the highly variable absorption kinetics of itraconazole capsules. Itraconazole is a weakly basic drug, and dissolution of the drug is pH-dependent; thus the drug requires an acidic gastric environment for adequate absorption.
1 Numerous studies have documented substantial variation in itraconazole exposure owing to the effect of food, interaction with coadministered drugs, and adherence. 2 Guidelines recommend assessment of the exposure to itraconazole through therapeutic drug monitoring when the drug is used for treatment of systemic
